CreatorsPublishersAdvertisers
View more in
Medical & Biotech

Adverum Down After Clinical Development Shift for Gene Therapy Program

biospace.com
 2021-07-23

Cover picture for the articleShares of Adverum Biotechnologies plunged more than 20% in premarket trading after the company announced it was revising its clinical development plan for investigational gene therapy candidate ADVM-022 based on safety concerns in patients with diabetic macular edema (DME). On Thursday, Redwood City, Calif.-based Adverum announced that a review of...

www.biospace.com

Comments / 0

Comments / 0